P. Black, A. Kamat, Angela B Smith, S. Porten, R. Eapen, C. Mir, J. Teoh, T. Todenhöfer, Tian Zhang, K. Gust, S. Sridhar, S. Tanguay
{"title":"B2B: Bladder Cancer Summary","authors":"P. Black, A. Kamat, Angela B Smith, S. Porten, R. Eapen, C. Mir, J. Teoh, T. Todenhöfer, Tian Zhang, K. Gust, S. Sridhar, S. Tanguay","doi":"10.48083/NJCD1236","DOIUrl":null,"url":null,"abstract":"The Bench-to-Bedside Uro-Oncology GU Cancer Triad Meeting was organized by the Société Internationale d’Urologie and was held online on May 21st and 22nd, 2021. The session on bladder cancer (BCa) took place on the morning of Friday, May 21st, and was chaired by Dr. Peter C. Black (Canada) and Dr. Ashish Kamat (United States). This session covered practice-changing advances on the horizon for BCa, the use of urine markers in BCa management, evolving therapies for non-muscle-invasive BCa (NMIBC), and recent advances for systemic therapy for muscle-invasive BCa (MIBC) and advanced urothelial carcinoma","PeriodicalId":103607,"journal":{"name":"Proceedings from the SIU B2B Uro-Oncology: GU Cancers Triad Virtual Meeting May 21–22, 2021","volume":"231 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings from the SIU B2B Uro-Oncology: GU Cancers Triad Virtual Meeting May 21–22, 2021","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48083/NJCD1236","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The Bench-to-Bedside Uro-Oncology GU Cancer Triad Meeting was organized by the Société Internationale d’Urologie and was held online on May 21st and 22nd, 2021. The session on bladder cancer (BCa) took place on the morning of Friday, May 21st, and was chaired by Dr. Peter C. Black (Canada) and Dr. Ashish Kamat (United States). This session covered practice-changing advances on the horizon for BCa, the use of urine markers in BCa management, evolving therapies for non-muscle-invasive BCa (NMIBC), and recent advances for systemic therapy for muscle-invasive BCa (MIBC) and advanced urothelial carcinoma
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
